Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Jan 2;20(1):21-8.
doi: 10.1097/01.aids.0000196172.35056.b7.

The impact of transmitted drug resistance on the natural history of HIV infection and response to first-line therapy

Deenan Pillay  1 , Krishnan Bhaskaran, Suzanne Jurriaans, Maria Prins, Bernard Masquelier, Francois Dabis, Robert Gifford, Claus Nielsen, Court Pedersen, Claudia Balotta, Giovanni Rezza, Marta Ortiz, Carmen de Mendoza, Claudia Kücherer, Gabriele Poggensee, John Gill, Kholoud Porter; CASCADE Virology Collaboration
Affiliations

The impact of transmitted drug resistance on the natural history of HIV infection and response to first-line therapy

Deenan Pillay et al. AIDS. .

Abstract

Background: Transmission of drug-resistant HIV-1 is well recognized. However, the impact of such transmission on natural history of infection remains unknown.

Methods: Three hundred HIV-1-infected, antiretroviral-naive individuals, recruited between 1987 and 1993, and with resistance tests undertaken within 18 months of infection were assessed. We estimated the impact of transmitted drug resistance (TDR) on subsequent CD4 cell count decline in the absence of treatment. We also used Kaplan-Meier methods to assess the response to antiretroviral therapy based on the number of active drugs utilized (according to genotypic resistance results).

Results: Infection with any form of drug-resistant HIV-1 was associated with a steeper decline of CD4 cell count over the first year of infection. Estimated rates of decline in the first year were 5.0 [95% confidence interval (CI), 2.8-7.3] and 1.7 (95% CI, 0.8-2.6) radicalCD4 cells per year for TDR and no TDR, respectively (P = 0.005). For an individual at a CD4 cell count of 500 cells/microl at seroconversion, these rates correspond to a CD4 cell loss of 199 and 73 cells/microl, respectively, in the first year. Thereafter we found no evidence of a difference in the rate of CD4 cell decline (P = 0.32). Initiation of HAART after calendar year 2000, but not number of active drugs, was associated with improved responses.

Conclusions: The impact of transmitted HIV-1 drug resistance on CD4 cell decline is time dependent, with greater rates of decline in the first year following infection. We found no evidence of a longer term effect of TDR on natural history of HIV-1 infection.

PubMed Disclaimer

Publication types